Steegmann, J L
Baccarani, M
Breccia, M
Casado, L F
García-Gutiérrez, V
Hochhaus, A
Kim, D-W
Kim, T D
Khoury, H J
Le Coutre, P
Mayer, J
Milojkovic, D
Porkka, K
Rea, D
Rosti, G
Saussele, S
Hehlmann, R
Clark, R E
Article History
Received: 29 February 2016
Accepted: 18 April 2016
First Online: 28 April 2016
Competing interests
: Authors declare the following relationships with pharmaceutical companies: Amgen- receipt of honoraria (GR); Ariad—receipt of honoraria: (JLS, MB, MaB, VG-G, DWK, HJK, PLC, DM, DR, GR and SS) and research funding (JLS, LFC, VG-G, AH, DWK, PLC and GR); Bristol–Myers–Squibb—receipt of honoraria (JLS, MB, MaB, LFC, VG-G, AH, DWK, HJK, PLC, DM, KP, DR, GR, SS, RH and REC), research funding (JLS, LFC, VG-G, DWK, JM, KP, GR, SS and REC) and nonfinancial support (JM); MSD- research support (AH); Novartis—receipt of honoraria (JLS, MB, MaB, LFC, VG-G, DWK, HJK, PLC, DM, KP, DR, GR, SS and REC), research funding (JLS, LFC, VG-G, AH, DWK, JM, KP, GR, SS, RH and REC) and nonfinancial support (JM); ILYANG—receipt of honoraria (DWK) and research funding (DWK); Pfizer-receipt of honoraria (JLS, MB, MaB, LFC, VG-G, DWK, HJK, PLC, DM, KP, DR, GR, SS and REC) and research funding (JLS, LFC, VG-G, AH, DWK, KP, GR and REC); Roche—receipt of honoraria (GR); Sanofi-receipt of honoraria (REC) and research funding (REC); Teva—receipt of honoraria (HJK).